Humaclot (Human Coagulation Factor Viii)

Humaclot is indicated for the management of bleeding episodes and peri‑operative prophylaxis in individuals with hemophilia A.

• Treatment of acute spontaneous or trauma‑related bleeds in hemophilia A patients.
• Surgical or dental procedure prophylaxis to prevent intra‑operative bleeding.
• Routine prophylactic therapy to reduce frequency of bleeding episodes.
• On‑demand replacement therapy when factor VIII levels fall below therapeutic thresholds.
• Use in patients with severe or moderate factor VIII deficiency as determined by laboratory testing.

• Humaclot provides functional human factor VIII, a cofactor in the intrinsic pathway of the coagulation cascade. By binding to activated factor IX on phospholipid surfaces, it restores the tenase complex, enabling efficient conversion of factor X to Xa and generation of thrombin, which leads to fibrin clot formation. The replacement of deficient factor VIII normalizes clotting times in hemophilia A.

Adverse reactions to Humaclot may vary in frequency and severity.

Common

• Mild infusion‑site reactions such as erythema, warmth, or tenderness.
• Transient fever or chills occurring during or shortly after administration.
• Headache or fatigue reported by some patients.
• Nausea or mild gastrointestinal discomfort.

Serious

• Development of inhibitory antibodies (inhibitors) against factor VIII, reducing efficacy.
• Anaphylactic or severe hypersensitivity reactions, including rash, bronchospasm, or hypotension.
• Thrombotic events, though rare, especially if dosing exceeds recommended levels.

Clinicians should observe several precautions when prescribing Humaclot to ensure safety and effectiveness.

• Verify factor VIII deficiency and baseline inhibitor status before initiation.
• Monitor for development of inhibitors during regular treatment intervals.
• Use aseptic technique and inspect the solution for particulates before infusion.
• Adjust dosage in patients with renal or hepatic impairment as guided by laboratory values.
• Counsel patients on signs of allergic reactions and instruct them to seek immediate medical care if they occur.
• Store the product at recommended temperatures; avoid freezing to preserve protein integrity.

Humaclot may interact with other agents that affect hemostasis or immune response.

Avoid

• Concomitant use of other factor concentrates without specialist guidance, which may increase thrombosis risk.
• Administration of high‑dose pro‑coagulant agents (e.g., activated prothrombin complex concentrates) that could potentiate clot formation.

Use with caution

• Immunosuppressive therapies that may alter inhibitor development.
• Antifibrinolytic drugs (e.g., tranexamic acid) when combined with factor VIII, requiring careful monitoring.
• Vaccinations administered shortly before or after infusion, as they may affect immune response.